Online inquiry

IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12691MR)

This product GTTS-WQ12691MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets DLL4 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_019074.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 54567
UniProt ID Q9NR61
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ12691MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5301MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ6468MR IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CT-P-59
GTTS-WQ13504MR IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PRX002
GTTS-WQ13208MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-04950615
GTTS-WQ15611MR IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA VAY-736
GTTS-WQ14858MR IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA SGN-CD33A
GTTS-WQ2695MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 785
GTTS-WQ666MR IVTScrip™ mRNA-Anti-CD276, 8H9(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 8H9
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW